Market Overview

UPDATE: Deutsche Bank Reiterates on Amgen Following Biosimilar Conference

Share:
Related AMGN
Barclays Says Acceleration For Amgen Could Be A Challenge
12 Must Watch Stocks for July 27, 2016
Global Leaders Trinseo, Atlassian Set To Report, But Expectations Differ (Investor's Business Daily)

In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target from $138.00 to $142.00.

In the report, Deutsche Bank noted, “We attended a biosimilar conference in order to learn more about the OPP'Y for Amgen. We came away with a greater understanding as to the impact of Biosimilars on AMGN's base biz & have adjusted our model accordingly. We also grew more comfortable in the Biosmilar opp'y for AMGN. We now include a probability adjusted Biosimilar revs beyond 2017 & note net/net biosimilars have a positive NPV to AMGN. Please ask for our Biosimilar APP.”

Amgen closed on Tuesday at $115.46.

Latest Ratings for AMGN

DateFirmActionFromTo
Jul 2016CitigroupMaintainsNeutral
Jul 2016JefferiesMaintainsBuy
Jul 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Price Target Analyst Ratings

 

Related Articles (AMGN)

View Comments and Join the Discussion!